In 2019, the FDA approved a regimen comprising the inhibitor apelalisib in combination with fulvestrant, targeting the PI3Kα isoforms, as well as the regimen of capivaserti in combination with fulvestrant, targeting three AKT isoforms to be used in patients with HR-positive, HER2-negative breast cancer harboring PIK3CA mutations. Here, PIK3CA is linked to breast carcinoma.